Physician profile
Amanda N Lewis
NPI 1861639395
$1,633.40
in general payments reported to CMS, 2019-2025
26 companies · $506 in 2025
The $506 reported for 2025 was more than what 80% of Surgical providers received nationally (typical 2025 total: $146).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2022: $27.67 · 2023: $361 · 2024: $739 · 2025: $506.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $1,606.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $1,605.73 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Corcept Therapeutics | $240.28 | 2023-2025 | Korlym |
| Xeris Pharmaceuticals, INC. | $202.54 | 2023-2025 | Recorlev, Gvoke Hypopen |
| Tandem Diabetes Care, INC. | $147.91 | 2023-2025 | T:Slim X2 Insulin Pump With Control-Iq |
| Bayer Healthcare Pharmaceuticals INC. | $145.21 | 2023-2025 | |
| Lilly USA, LLC | $131.12 | 2024-2025 | Jardiance, Mounjaro, Zepbound |
| Chiesi USA, INC. | $83.15 | 2024-2025 | Mycapssa |
| Medtronic, INC. | $80.68 | 2024-2025 | Intellis Adaptivestim, Inceptiv |
| Hologic Sales and Service, LLC | $67.40 | 2023-2024 | Coolseal Generator |
| Ascendis Pharma Endocrinology INC | $58.26 | 2023-2025 | Yorvipath |
| Amgen INC. | $50.25 | 2023-2025 | Evenity, Prolia, Prolia |
| Beta Bionics, INC. | $47.31 | 2023-2025 | Ilet Bionic Pancreas, Ilet Insulin Infusion Kit Contact Detach, Ilet Insulin Infusion Kit Inset |
| Insulet Corporation | $45.58 | 2023-2024 | Omnipod |
| Dexcom, INC. | $43.94 | 2023 | Dexcom G6 Transmitter |
| Abbvie INC. | $40.80 | 2024-2025 | |
| Cequr Corporation | $39.06 | 2025 | Cequr Simplicity |
Show all 26 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Boehringer Ingelheim Pharmaceuticals, INC. | $29.36 | 2024 | Jardiance |
| Nevro Corp. | $23.64 | 2024 | Senza |
| Mannkind Corporation | $23.10 | 2023 | Afrezza |
| Baxter Healthcare | $22.25 | 2025 | Perclot |
| Novartis Pharmaceuticals Corporation | $21.61 | 2024 | |
| Novo Nordisk INC | $16.71 | 2025 | Ozempic, Rybelsus |
| Paratek Pharmaceuticals, INC. | $16.49 | 2025 | Nuzyra |
| Halozyme INC | $15.59 | 2023 | |
| Innocoll Pharmaceuticals Limited | $15.51 | 2022 | |
| Currax Pharmaceuticals LLC | $13.49 | 2023 | Contrave, Onzetra Xsail |
| Baudax Bio INC. | $12.16 | 2022 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Amanda Lewis listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.